R. Lamy
Impact in
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 20
- Cancer Immunotherapy and Biomarkers 10
- Lung Cancer Research Studies 9
- Pancreatic and Hepatic Oncology Research 3
-
- Lung Cancer Treatments and Mutations 13
- Lung Cancer Diagnosis and Treatment 4
- Brain Metastases and Treatment 2
- Co-authors
- C. Chouaïd (15 shared papers)Florian Guisier (9 shared papers)P. Fournel (5 shared papers)H. Doubre (4 shared papers)Olivier Bylicki (3 shared papers)M. Pérol (3 shared papers)Henri Janicot (4 shared papers)F. Viñas (3 shared papers)
- Journals
- Annals of Oncology (5 papers)Journal of Thoracic Oncology (4 papers)Cancer Medicine (3 papers)Oncotarget (2 papers)Lung Cancer (2 papers)
- Partner nations
- FranceUnited StatesLuxembourg
In The Last Decade
R. Lamy
30 papers receiving 656 citations
R. Lamy's Hit Papers
Peers
Comparison fields: 5 of 46
- Oncology 438
- Pulmonary and Respiratory Medicine 328
- Cancer Research 112
- Pathology and Forensic Medicine 49
- Hepatology 15
Countries citing papers authored by R. Lamy
This map shows the geographic impact of R. Lamy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Lamy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Lamy more than expected).
Fields of papers citing papers by R. Lamy
This network shows the impact of papers produced by R. Lamy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Lamy. The network helps show where R. Lamy may publish in the future.
Co-authors
The 25 scholars most cited alongside R. Lamy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018 Hit paper breakdown → | 2020 | 223 |
| 2 | 2012 | 185 | |
| 3 | 2020 | 42 | |
| 4 | 2017 | 27 | |
| 5 | 2020 | 22 | |
| 6 | 2018 | 20 | |
| 7 | 1988 | 18 | |
| 8 | 2015 | 15 | |
| 9 | 2015 | 14 | |
| 10 | 2020 | 12 | |
| 11 | 2018 | 10 | |
| 12 | 2022 | 10 | |
| 13 | 2011 | 10 | |
| 14 | 2019 | 7 | |
| 15 | 2020 | 6 | |
| 16 | 2018 | 5 | |
| 17 | 2021 | 5 | |
| 18 | 2022 | 5 | |
| 19 | 2019 | 5 | |
| 20 | 2021 | 4 |
About R. Lamy
R. Lamy is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Pathology and Forensic Medicine, having authored 32 papers that have together received 665 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Research Studies (9 papers), Lung Cancer Diagnosis and Treatment (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Brain Metastases and Treatment (2 papers), Cancer Mechanisms and Therapy (1 paper) and Streptococcal Infections and Treatments (1 paper). The work is most often cited by research in Oncology (438 citations), Pulmonary and Respiratory Medicine (328 citations), Cancer Research (112 citations), Pathology and Forensic Medicine (49 citations) and Hepatology (15 citations). R. Lamy has collaborated with scholars based in France, United States and Luxembourg. Frequent co-authors include C. Chouaïd, Florian Guisier, P. Fournel, H. Doubre, Olivier Bylicki, M. Pérol, Henri Janicot, F. Viñas, Charles Ricordel and L. Falchero. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Cancer Medicine, Oncotarget and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.